A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

​ Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: ESG206; Drug: ESG206; Drug: Placebo

Sponsors: Shanghai Escugen Biotechnology Co., Ltd

Not yet recruiting Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Drug: ESG206; Drug: ESG206; Drug: Placebo
Sponsors: Shanghai Escugen Biotechnology Co., Ltd
Not yet recruiting